Advanced Search

    column
    Research Progress of Limited-Stage Small Cell Lung Cancer Treatment Mode Through ADRIATIC Study
    CHENG Ying
    2024, 24(3): 129-132. DOI: 10.12019/j.issn.1671-5144.202406006
    Abstract PDF
    LAURA Study Established a New Standard Treatment for Locally Advanced NSCLC With EGFR Mutation
    PAN Yi
    2024, 24(3): 133-134. DOI: 10.12019/j.issn.1671-5144.202406009
    Abstract PDF
    Can Patients With Advanced NSCLC Enjoy "Drug Holiday"?----Comment on the Adaptive De-Escalate Treatment of Targeted Drugs Guided by ctDNA in Patients With Advanced NSCLC
    AI Xing-hao, LU Shun
    2024, 24(3): 135-137. DOI: 10.12019/j.issn.1671-5144.202406017
    Abstract PDF
    Orient-31 Model Discussion: Immunotherapy can Be Used After Drug Resistance of Advanced NSCLC With Oncogenic Driver Mutation
    JIE Guang-ling, NIU Xiao-min
    2024, 24(3): 138-141. DOI: 10.12019/j.issn.1671-5144.202402008
    Abstract PDF
    Adjuvant Immunotherapy Should not be Used for Early-Stage Non-Small Cell Lung Cancer Patients Achieving a Complete Pathological Response Post Neoadjuvant Chemo-Immunotherapy
    ZHANG Xiao-long, PU qiang
    2024, 24(3): 142-144. DOI: 10.12019/j.issn.1671-5144.202403011
    Abstract PDF
    FLAURA2 Study: Mode Exploration of First-Line Treatment for Advanced NSCLC With EGFR Mutation
    WANG Li-jie
    2024, 24(3): 145-149. DOI: 10.12019/j.issn.1671-5144.202404040
    Abstract PDF
    Expression and Clinical Significance of CKAP2L in Ovarian Cancer
    CHAI Ying, NI Yan, ZHAO Yuan, WANG Xiao, YANG Xiao-jie
    2024, 24(3): 150-154, 177. DOI: 10.12019/j.issn.1671-5144.202308029
    Abstract PDF
    Appraisal of Guidelines and Consensuses on Management of Pulmonary Nodules
    LI Yan-long, ZHENG Xin-ze, YANG Hong-mei, DAI Ming-yuan, CHEN Jia-hui, LI Xue-wei, LI Ling, LIU Yan-mei, AN Bo, YU Ling, SUN Ling-ling, LIN Li-zhu
    2024, 24(3): 155-172. DOI: 10.12019/j.issn.1671-5144.202402006
    Abstract PDF
    The Value of Flow Cytometry Analysis in the Diagnosis of Chronic Myelomonocytic Leukemia
    WANG Lin, DU Xin
    2024, 24(3): 173-177. DOI: 10.12019/j.issn.1671-5144.202401024
    Abstract PDF
    Research Progress of the Drug Resistance Mechanism of the Third-Generation ALK Inhibitor Lorlatinib in NSCLC
    TIAN Hong-xia, ZHANG Xu-chao
    2024, 24(3): 178-192. DOI: 10.12019/j.issn.1671-5144.202404009
    Abstract PDF